Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR2 fusion
i
Other names:
FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2263
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR2 overexpression (8)
FGFR2 expression (3)
FGFR2b expression (3)
FGFR2b overexpression (2)
FGFR2b overexpression + HER-2 negative (2)
FGFR2b positive (2)
FGFR2 underexpression (1)
FGFR2 underexpression + FGFR3 overexpression (1)
FGFR2 underexpression + FGFR3 expression (0)
HER-2 negative + FGFR2b overexpression (0)
FGFR2 overexpression (8)
FGFR2 expression (3)
FGFR2b expression (3)
FGFR2b overexpression (2)
FGFR2b overexpression + HER-2 negative (2)
FGFR2b positive (2)
FGFR2 underexpression (1)
FGFR2 underexpression + FGFR3 overexpression (1)
FGFR2 underexpression + FGFR3 expression (0)
HER-2 negative + FGFR2b overexpression (0)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
futibatinib
Sensitive
:
A1
futibatinib
Sensitive: A1 - Approval
futibatinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
FGFR2 fusion
Biliary Tract Cancer
FGFR2 fusion
Biliary Tract Cancer
futibatinib
Sensitive: A1 - Approval
futibatinib
Sensitive
:
A1
futibatinib
Sensitive: A1 - Approval
futibatinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
FGFR inhibitor
Sensitive: A2 - Guideline
FGFR inhibitor
Sensitive
:
A2
FGFR inhibitor
Sensitive: A2 - Guideline
FGFR inhibitor
Sensitive
:
A2
FGFR2 fusion
Urothelial Cancer
FGFR2 fusion
Urothelial Cancer
erdafitinib
Sensitive: B - Late Trials
erdafitinib
Sensitive
:
B
erdafitinib
Sensitive: B - Late Trials
erdafitinib
Sensitive
:
B
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
KIN-3248
Sensitive: B - Late Trials
KIN-3248
Sensitive
:
B
KIN-3248
Sensitive: B - Late Trials
KIN-3248
Sensitive
:
B
FGFR2 fusion
Solid Tumor
FGFR2 fusion
Solid Tumor
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
FGFR2 fusion
Glioma
FGFR2 fusion
Glioma
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
FGFR2 fusion
Gastric Cancer
FGFR2 fusion
Gastric Cancer
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
FGFR2 fusion
Breast Cancer
FGFR2 fusion
Breast Cancer
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
FGFR2 fusion
Hepatocellular Cancer
FGFR2 fusion
Hepatocellular Cancer
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.